Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Drug-Only approach may prevent Post-Procedure pancreatitis without stent risks

NCT ID NCT07117318

Prevention Sponsor: Air Force Military Medical University, China Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares two ways to prevent pancreatitis after a procedure called ERCP: giving a rectal anti-inflammatory drug (NSAID) alone versus the drug plus placing a small tube (stent) in the pancreas. The trial enrolls about 1,278 high-risk patients aged 18-90 who have not had prior pancreatic stenting. The goal is to see if the drug alone works just as well, avoiding the extra complexity and risks of stent placement.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 1,278 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2025

Expected to finish

Jun 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 90 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 18-90 years old patients with native papilla who planned to undergo ERCP * high-risk patients for post-ERCP pancreatitis must meet one or more following criteria: clinical suspicion of sphincter of Oddi dysfunction, a history of PEP, pancreatic sphincterotomy, precut sphincterotomy, difficult cannulation (\>5 cannulation attempts, or \>5mins cannulation time, or \>1 unintentional pancreatic duct cannulation), or ballon dilatation of an intact biliary sphincter ≤ 1 min, double-wire cannulation. Additionally, patients were considered high-risk if they fulfilled two or more of the following minor criteria: female gender under 50 years old, a history of recurrent pancreatitis (two or more episodes), three or more contrast injections into the pancreatic duct with at least one injection reaching the tail of the pancreas, opacification of pancreatic acini, or brush cytology performed on the pancreatic duct. Exclusion Criteria: * Previous biliary sphincterotomy and papillary large balloon dilation * Planned for placements of pancreatic duct stents (eg. pancreatic duct strictures, planned ampullectomy) * Allergy to NSAIDs * The administration of NSAIDs within 7 days * Not suitable for NSAIDs administration (gastrointestinal hemorrhage within 4 weeks, renal dysfunction \[Cr \>1.4mg/dl=120umol/l\]; presence of coagulopathy before the procedure) * Acute pancreatitis within 7 days before ERCP or acute pancreatitis with obvious Pancreatic edema and peripancreatic fluid collections * Hemodynamical instability * Pregnancy or lactation * high-risk patients with pancreatic duct wire passages

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Non-steroid anti-inflammatory drugs are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute pancreatitis prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Non-steroid anti-inflammatory drugs Pancreatic duct stent placement Post-ercp acute pancreatitis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    15 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • 986 Hospital of Xijing Hospital

    RECRUITING

    Xi'an, Shaanxi, 710000, China

  • Affiliated Hangzhou First People's Hospital

    NOT_YET_RECRUITING

    Hangzhou, Zhejiang, 310000, China

  • Department of Endoscopy, Eastern Hepatobiliary Hospital, Second Military Medical University

    RECRUITING

    Shanghai, Shanghai Municipality, 201823, China

  • Department of Gastroenterology, Fujian Medical University Xiamen Humanity Hospital

    RECRUITING

    Xiamen, Fujian, 361000, China

  • Department of Gastroenterology, Huaihe Hospital of Henan University

    RECRUITING

    Kaifeng, Henan, 475000, China

  • Department of Gastroenterology, The 960th Hospital of the PLA

    RECRUITING

    Jinan, Shandong, 250000, China

  • Department of gastroenterology, Second Affiliated Hospital of Chongqing Medical University

    RECRUITING

    Chongqing, Chongqing Municipality, 400010, China

  • Harbin Medical University Affiliated Fourth Hospital

    RECRUITING

    Harbin, Heilongjiang, 150000, China

  • Shandong Provincial Third Hospital

    NOT_YET_RECRUITING

    Jinan, Shandong, 250000, China

  • The Second Affiliated Hospital of Harbin Medical University

    RECRUITING

    Harbin, Heilongjiang, 150000, China

  • The Third Xiangya Hospital of Central South University

    NOT_YET_RECRUITING

    Changsha, Hunan, 410000, China

  • The first medical center, Chinese PLA General Hospital

    NOT_YET_RECRUITING

    Beijing, Beijing Municipality, 100000, China

  • Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

    RECRUITING

    Wuhan, Hubei, 430000, China

  • Xijing of Digestive Diseases

    RECRUITING

    Xi'an, Shaanxi, China

  • the First Affiliated Hospital, Zhejiang University School of Medicine

    RECRUITING

    Hangzhou, Zhejiang, 310000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.